1995
DOI: 10.2165/00002018-199513010-00004
|View full text |Cite
|
Sign up to set email alerts
|

Slow-Acting Antirheumatic Drugs Drug Interactions of Clinical Significance

Abstract: The slow-acting antirheumatic drugs (SAARDs) are being used in an increasing proportion of patients with rheumatoid arthritis (RA). The potential toxicity of each drug is well recognised. Many patients with RA will be on other medications and the potential for adverse drug interactions with SAARDs is not so well publicised. There have, over the years, been numerous reports of possible drug interactions with SAARDs but few of these are clinically relevant. It is, however, vitally important that the physician is… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

1997
1997
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 27 publications
0
2
0
Order By: Relevance
“…Although information on potential DDIs is available from reviews, [3][4][5][6] product leaflets, textbooks, 7,8 and the medical literature, several barriers impede recognition of the clinical importance of a DDI. The evidence for most DDIs is based on case reports or poorly documented clinical information.…”
Section: Introductionmentioning
confidence: 99%
“…Although information on potential DDIs is available from reviews, [3][4][5][6] product leaflets, textbooks, 7,8 and the medical literature, several barriers impede recognition of the clinical importance of a DDI. The evidence for most DDIs is based on case reports or poorly documented clinical information.…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, angiogenesis is important for leukocyte extravasation and thus for pathogenesis of RA ( Szekanecz et al, 1998 ). Therapeutic agents for rheumatoid arthritis include non-steroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen, and celecoxib) ( Alaaeldin et al, 2021 ), slow-acting anti-rheumatism drugs (e.g., penicillamine and hydroxychloroquine) ( Munro and Sturrock., 1995 ), and adrenocorticosteroids (e.g., cortisone, hydrocortisone and prednsion) ( Boutet et al, 2021 ). However, most of them display long-term adverse effects and toxicity ( Munro and Sturrock., 1995 ; Alaaeldin et al, 2021 ; Boutet et al, 2021 ).…”
Section: Introductionmentioning
confidence: 99%